Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.
Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.
The patient in UK was enrolled at St. Pancras Clinical Research in London. This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open.
Actinogen’s trial will enrol 174 patients at 20 research sites across Australia, the U.S. and the UK.
To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial.
The first XanADu patient will complete the study next month, having reached the end of the 12-week dosing period, and now entering the 4-week follow up phase of the trial.
It is estimated that there are nearly 50 million people with Alzheimer’s disease worldwide, increasing to 131 million by 2050, making it critical to find effective new drugs to treat the disease.
The progress in the development of Xanamem is expected to provide an opportunity for Actinogen to make a profound difference to Alzheimer’s patients and their carers worldwide.
Actinogen ended the June quarter with $3.98 million in cash.